Laser boost for leishmaniasis treatment?
NCT ID NCT07652021
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding a fractional CO₂ laser to standard Glucantime injections helps heal skin sores from leishmaniasis faster and with less scarring. About 150 adults will be randomly assigned to get either the injection alone or the injection plus laser. Researchers will track how quickly sores heal and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Meglumine antimoniate (Glucantime) injections and fractional CO₂ laser therapy
- What this could lead to
- If it works, this combination could speed up healing and improve scarring for people with cutaneous leishmaniasis.
- What could go wrong
- This is a small, early-phase trial (150 people) that hasn't started yet. The laser may not add benefit or could cause side effects like burns or pain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria * Age ≥18 years and ≤60 years. * Clinically diagnosed and/or smear-confirmed cutaneous leishmaniasis. * Presence of at least one measurable cutaneous lesion suitable for treatment. * Willing and able to provide written informed consent. * Willing to undergo study treatment and comply with scheduled follow-up visits. Exclusion Criteria * Previous treatment for the current lesion(s). * Mucocutaneous or visceral leishmaniasis. * Pregnancy or lactation. * Severe systemic illness or immunosuppression. * Known hypersensitivity or contraindication to study interventions. * Lesions located within 2 cm of the eyelid margin or mucosal lip (laser safety concern). * Inability or unwillingness to comply with study procedures or follow-up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutaneous leishminiasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Combined military hospital peshawar
Peshawar, Khyber Pukhtunkhwa, 25000, Pakistan